QVM149
Total Payments
$5.5M
Transactions
138
Doctors
5
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $12,842 | 5 | 0 |
| 2019 | $294,730 | 34 | 0 |
| 2018 | $1.6M | 52 | 0 |
| 2017 | $3.6M | 47 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $5.5M | 132 | 99.9% |
| Travel and Lodging | $2,939 | 6 | 0.1% |
Payments by Type
Research
$5.5M
132 transactions
General
$2,939
6 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 3 PERIOD COMPLETE CROSSOVER STUDY TO ASSESS THE BRONCHODILATOR EFFECTS AND SAFETY OF GLYCOPYRRONIUM BROMIDE NAV237 25 AND 50 UG O D IN ASTHMA PATIENTS | Novartis Pharmaceuticals Corporation | $2.1M | 0 |
| TO ASSESS THE BRONODILATOR EFFFECT OF ORALLY INHALED INDACATEROL SALTS MALEATE AND ACETATE IN PATIENTS WITH PERSISTENT ASTHMA COMPARED WITH PLACEBO AS MEASURED BY THROUGH FEV1 AFTER 14 DAYS OF TREATMENT | Novartis Pharmaceuticals Corporation | $1.9M | 0 |
| A MULTI CENTER RANDOMIZED 52 WEEKS TREATMENT DOUBLE BLIND TRIPLE DUMMY STUDY TO ASSESS THE EFFICACY AND SAFETY OF QMF149 COMPARED WITH MOMETASONE FUROATE AND SALMETEROL FLUTICASONE | Novartis Pharmaceuticals Corporation | $1.5M | 0 |
Top Doctors Receiving Payments for QVM149
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Dartmouth, MA | $5.5M | 132 |
| , MD | Allergy & Immunology | North Dartmouth, MA | $784.00 | 2 |
| , M.D | Allergy & Immunology | Raleigh, NC | $696.00 | 1 |
| , M.D | Allergy & Immunology | Saint Louis, MO | $559.00 | 1 |
| , M.D | Allergy | Medford, OR | $490.00 | 1 |
| , MD | Allergy & Immunology | Skillman, NJ | $410.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $5.5M
- Total Doctors 5
- Transactions 138
About QVM149
QVM149 is a drug associated with $5.5M in payments to 5 healthcare providers, recorded across 138 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $12,842 was paid across 5 transactions to 0 doctors.
The most common payment nature for QVM149 is "Unspecified" ($5.5M, 99.9% of total).
QVM149 is associated with 3 research studies, including "A MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 3 PERIOD COMPLETE CROSSOVER STUDY TO ASSESS THE BRONCHODILATOR EFFECTS AND SAFETY OF GLYCOPYRRONIUM BROMIDE NAV237 25 AND 50 UG O D IN ASTHMA PATIENTS" ($2.1M).